Innate Pharma Future Growth

Future criteria checks 2/6

Innate Pharma is forecast to grow earnings and revenue by 36.6% and 26.2% per annum respectively. EPS is expected to grow by 103.7% per annum. Return on equity is forecast to be -132.3% in 3 years.

Key information

36.6%

Earnings growth rate

103.7%

EPS growth rate

Biotechs earnings growth	42.4%
Revenue growth rate	26.2%
Future return on equity	-132.3%
Analyst coverage	Good
Last updated	19 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:IDD - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	103	-14	69	174	5
12/31/2025	86	10	34	99	6
12/31/2024	54	-22	28	38	6
6/30/2024	34	-34	-20	-18	N/A
3/31/2024	48	-21	-28	-25	N/A
12/31/2023	62	-8	-35	-33	N/A
9/30/2023	57	-35	-34	-32	N/A
6/30/2023	52	-63	-33	-32	N/A
3/31/2023	55	-60	-27	-25	N/A
12/31/2022	58	-58	-20	-19	N/A
9/30/2022	57	-40	-24	-23	N/A
6/30/2022	57	-22	-28	-26	N/A
3/31/2022	41	-34	-44	-42	N/A
12/31/2021	25	-45	-60	-58	N/A
6/30/2021	46	-8	-27	-25	N/A
3/31/2021	58	-4	-45	-38	N/A
12/31/2020	70	-1	-63	-52	N/A
9/30/2020	67	-54	-78	-67	N/A
6/30/2020	63	-44	-93	-83	N/A
3/31/2020	75	-33	-62	-24	N/A
12/31/2019	85	8	-30	35	N/A
9/30/2019	108	5	-17	48	N/A
6/30/2019	130	31	-4	61	N/A
3/31/2019	112	17	-19	14	N/A
12/31/2018	94	3	-34	-33	N/A
9/30/2018	70	-19	-49	-46	N/A
6/30/2018	46	-40	-64	-59	N/A
3/31/2018	45	-44	N/A	-53	N/A
12/31/2017	44	-48	N/A	-48	N/A
9/30/2017	55	-28	N/A	-43	N/A
6/30/2017	66	-8	N/A	-38	N/A
3/31/2017	66	3	N/A	-37	N/A
12/31/2016	66	13	N/A	-37	N/A
9/30/2016	53	5	N/A	-33	N/A
6/30/2016	41	-2	N/A	-29	N/A
3/31/2016	33	-4	N/A	86	N/A
12/31/2015	25	-7	N/A	202	N/A
9/30/2015	17	-13	N/A	200	N/A
6/30/2015	8	-19	N/A	199	N/A
3/31/2015	8	-19	N/A	91	N/A
12/31/2014	8	-20	N/A	-18	N/A
9/30/2014	11	-15	N/A	-15	N/A
6/30/2014	14	-10	N/A	-12	N/A
3/31/2014	15	-6	N/A	-11	N/A
12/31/2013	17	-3	N/A	-11	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IDD is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IDD is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IDD is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IDD's revenue (26.2% per year) is forecast to grow faster than the German market (5.7% per year).

High Growth Revenue: IDD's revenue (26.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: IDD is forecast to be unprofitable in 3 years.

Innate Pharma Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

No longer forecast to breakeven

Forecast to breakeven in 2026

No longer forecast to breakeven

Recent updates

Innate Pharma S.A., Annual General Meeting, May 22, 2025

Innate Pharma S.A. to Report First Half, 2025 Results on Sep 17, 2025

Innate Pharma SA Announces Board Changes

Araris Biotech AG entered into an agreement to acquire ADC Transglutaminase Conjugation Technology Patents Portfolio from Innate Pharma S.A. (ENXTPA:IPH).

First half 2024 earnings released: €0.31 loss per share (vs €0.021 profit in 1H 2023)

New minor risk - Profitability

New minor risk - Share price stability

Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial

New minor risk - Profitability

No longer forecast to breakeven

Innate Pharma SA Presents Positive Results from TELLOMAK Phase 2 Study with Lacutamab in Mycosis Fungoides

Innate Pharma Announces Advancement of Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients

Innate Pharma S.A. Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate

Forecast to breakeven in 2026

Full year 2023 earnings released: €0.094 loss per share (vs €0.73 loss in FY 2022)

Innate Pharma S.A. Announces First Patient Dosed in Phase 1/2 Study of IPH6501 in Relapsed /Refractory B-Cell Non-Hodgkin’s Lymphoma

Innate Pharma S.A. has filed a Follow-on Equity Offering in the amount of $75 million.

Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

Innate Pharma S.A. Announces New Clinical Data for Lacutamab and SAR443579/ IPH6101 at ASH 2023

Innate Pharma S.A. to Report Q2, 2024 Results on Sep 12, 2024

New minor risk - Share price stability

Innate Pharma S.A. Provides Update on Lacutamab Clinical Program

Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023

First half 2023 earnings released: EPS: €0.021 (vs €0.08 in 1H 2022)

Innate Pharma S.A. Announces Executive Changes

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma S.A. Announces First Patient Dosed in Matisse Trial of IPH5201 in Early Stage Lung Cancer

Innate Pharma Sa Highlights Increased Lacutamab Clinical Activity from Interim Results of Phase 2 Tellomak Study with Updated Olsen Criteria

Innate Pharma S.A. Highlights Proprietary Tetra-Specific Anket Nk Cell Engager Iph6501 At the Eha 2023 Congress

Innate Pharma S.A. Announces SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies

Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR'579 / IPH6101 in R/R AML

No longer forecast to breakeven

Innate Pharma SA Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology

Innate Pharma S.A. Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022

Innate Pharma S.A. to Report First Half, 2023 Results on Sep 14, 2023

Innate Pharma SA Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides

First half 2022 earnings released: EPS: €0.08 (vs €0.30 loss in 1H 2021)

Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study

Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer

Innate Pharma S.A. Announces Supervisory Board Changes

Innate Pharma Sa Announces the First Patient Was Dosed in A Phase 1/2 Clinical Trial

Innate Pharma SA Announces That Data from the Phase 2 Expansion Cohort

First half 2021 earnings released: €0.30 loss per share (vs €0.13 loss in 1H 2020)

Innate Pharma SA Announces Update on Avdoralimab Phase 2 Force Trial in COVID-19 Patients With Severe Pneumonia

Innate Pharma Presents Preliminary Data from TELLOMAK Trial Showing Clinical Response for Lacutamab in Mycosis Fungoides

Innate Pharma Presents New Data on Next-Generation NK Cell Engager Platform at FOCIS 2021 Annual Meeting

Innate Pharma S.A. Announces New Lacutamab Data from Tellomak Trial in Oral Presentation at Upcoming 16th International Conference on Malignant Lymphoma

Member of Supervisory Board Marcus Schindler has left the company

Full year 2020 earnings released

Full year 2020 earnings released

Innate Pharma S.A. Advances Lacutamab Clinical Development Program

Innate's First NK Cell Engager Selected by Sanofi as Drug Candidate for Development

Rosen Law Firm Reminds Innate Pharma S.A. Investors of Important December 22 Deadline in Securities Class Action

Innate Pharma S.A., Annual General Meeting, May 28, 2021

Innate Pharma Receives Prime Designation from the European Medicines Agency for Lacutamab in Sézary Syndrome

Innate Pharma S.A. Receives Prime Designation from the European Medicines Agency for Lacutamab in Sézary Syndrome

Innate Pharma Launches HopeConnectLearn: A New Online Resource for Hairy Cell Leukemia Patients

New 90-day low: €3.01

New 90-day low - €3.59

First half earnings released

New 90-day low - €5.11

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies